Correlates of Immunity Elicited by Live Yersinia pestis Vaccine

Braciale, Vivian L.; Nash, Michael J.; Sinha, Namita; Зудина, И. В.; Motin, Vladimir L.

doi:10.1007/978-1-59745-569-5_50

Cited by 9 publications

(10 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies demonstrated that Chinese-origin rhesus macaques immunized with EV76 or mice immunized with the Y. pestis ⌬smpB-ssrA mutant primed a higher anti-F1 IgG titer but an almost undetectable titer with respect to LcrV antigen (38,50), results that are consistent with other studies of animals immunized with the EV76 or KWC vaccine (51)(52)(53)(54)(55)(56)(57). Mice vaccinated with Y. pestis KIM5 (lacking pgm) generated the CD4 and CD8 T cells that synergistically conferred protection against plague, but T cells from those vaccinated mice could not recognize LcrV (47).…”

supporting

confidence: 88%

LcrV Delivered via Type III Secretion System of Live Attenuated Yersinia pseudotuberculosis Enhances Immunogenicity against Pneumonic Plague

et al. 2014

View full text Add to dashboard Cite

supporting

confidence: 88%

LcrV Delivered via Type III Secretion System of Live Attenuated Yersinia pseudotuberculosis Enhances Immunogenicity against Pneumonic Plague

et al. 2014

View full text Add to dashboard Cite

“…or intravenous route produced high level of anti-F1 antibody response, but no detectable level of antibodies against LcrV [92], which are consistent with other studies of animals immunized with the EV76 or KWC vaccine [79, 93–98]. Recently, Yang’s group [72] investigated the humoral and memory cellular immune responses in 65 plague patients recovered from Y. pestis infection during 16 years after infection using protein microarray and enzyme-linked immunosorbent spot assays.…”

Section: Altering Immune Response To Specific Antigens Of Y Pestis Tsupporting

confidence: 85%

Rational Considerations about Development of Live Attenuated Yersinia pestis Vaccines

Sun¹,

Curtiss²

2014

CPB

View full text Add to dashboard Cite

The risk of plague as a bioweapon has prompted increasing research efforts to develop plague vaccines due to its extreme virulence and the ease of its transmission. Subunit vaccines that contain F1 and LcrV antigens of Y. pestis have been tested for safety and immunogenicity, but doubts have been raised about whether subunit vaccines that engender antibody responses will protect against pneumonic plague, which requires both humeral and cellular immune responses for protection. The live, attenuated vaccine EV76, a pgm locus deficient Y. pestis strain, has been used for a long time in the Former Soviet Union and some Asian countries, but is not commercially available in the US and Europe due to safety concerns. However, the live attenuated Y. pestis vaccines are still considered to be the most effective way to prevent plague. In this review, we present our opinions about rationally creating live, safe and immunogenic Y. pestis vaccines with potential use for human based on established researches.

show abstract

“…Also, we report the presence of Pla cross-reactive linear B-cell epitopes that resulted in a strong reaction with this antigen of sera from naïve donors in ELISA. This was not totally surprising to us, since we saw an indication of this antibody cross-reactivity in our previous studies after probing Pla antigen with the panel of monoclonal antibodies [ 15 ], and also observed the Pla-reactive band on immunoblot with naïve human sera [ 25 ]. Interestingly, multiple vaccinations with LPV suppressed the antibody titers to Pla that were observed when recently (A-RV) and early (A-EV) groups of vaccinated donors were compared ( Fig 2 ).…”

Section: Discussionmentioning

confidence: 54%

“…The Hig-Tag-labeled Y . pestis recombinant proteins were purified as described previously for the panel of five antigens [ 25 ]. The quality of purification was evaluated with the silver stained PAGE.…”

Section: Methodsmentioning

confidence: 99%

Humoral and cellular immune responses to Yersinia pestis Pla antigen in humans immunized with live plague vaccine

et al. 2018

Self Cite

View full text Add to dashboard Cite

BackgroundTo establish correlates of human immunity to the live plague vaccine (LPV), we analyzed parameters of cellular and antibody response to the plasminogen activator Pla of Y. pestis. This outer membrane protease is an essential virulence factor that is steadily expressed by Y. pestis.Methodology/Principal findingsPBMCs and sera were obtained from a cohort of naïve (n = 17) and LPV-vaccinated (n = 34) donors. Anti-Pla antibodies of different classes and IgG subclasses were determined by ELISA and immunoblotting. The analysis of antibody response was complicated with a strong reactivity of Pla with normal human sera. The linear Pla B-cell epitopes were mapped using a library of 15-mer overlapping peptides. Twelve peptides that reacted specifically with sera of vaccinated donors were found together with a major cross-reacting peptide IPNISPDSFTVAAST located at the N-terminus. PBMCs were stimulated with recombinant Pla followed by proliferative analysis and cytokine profiling. The T-cell recall response was pronounced in vaccinees less than a year post-immunization, and became Th17-polarized over time after many rounds of vaccination.Conclusions/SignificanceThe Pla protein can serve as a biomarker of successful vaccination with LPV. The diagnostic use of Pla will require elimination of cross-reactive parts of the antigen.

show abstract

Correlates of Immunity Elicited by Live Yersinia pestis Vaccine

Cited by 9 publications

References 14 publications

LcrV Delivered via Type III Secretion System of Live Attenuated Yersinia pseudotuberculosis Enhances Immunogenicity against Pneumonic Plague

LcrV Delivered via Type III Secretion System of Live Attenuated Yersinia pseudotuberculosis Enhances Immunogenicity against Pneumonic Plague

Rational Considerations about Development of Live Attenuated Yersinia pestis Vaccines

Humoral and cellular immune responses to Yersinia pestis Pla antigen in humans immunized with live plague vaccine

Contact Info

Product

Resources

About